Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Based in the Guangdong-Hong Kong-Macao Greater Bay Area, HealthGen, a comprehensive pharmaceutical company focused on innovation, is committed to high-quality development in high-quality sectors.
Published Time：
2023-03-03
Facing the torrent of a new normal in the macroeconomy, continuous deepening of medical reforms, and increasingly fierce global competition in biotechnology, China's pharmaceutical industry is also constantly changing, and "high-quality development" has become the inevitable process of seeking optimal solutions under multiple challenges. Recently, HealthGen, a comprehensive pharmaceutical company located in Shenzhen, received the "High-tech Enterprise Certificate" jointly issued by the Shenzhen Municipal Science and Technology Innovation Committee, the Shenzhen Municipal Finance Bureau, and the Shenzhen Municipal Taxation Bureau of the State Taxation Administration.
Growing alongside the Greater Bay Area, HealthGen has always focused on the development of its pharmaceutical main business. Chairman Zhu Baoguo and the management team have formulated a clear and firm strategy for the company's sustainable development: focusing on the establishment of innovative drug and high-end complex preparation technology platforms and the layout and accumulation of drug research and development, continuously increasing R&D investment, and driving high-quality development through innovative R&D.
The 20th National Congress of the Communist Party of China report emphasized that "high-quality development is the primary task of comprehensively building a socialist modern country." Currently, high-tech enterprises have become the "leaders" leading high-quality development in various places, the "stabilizers" supporting the sustained and healthy development of the economy, and the "main force" of scientific and technological innovation activities. HealthGen, which has obtained the "High-tech Enterprise" certification, has received official authoritative recognition and support in multiple dimensions, including intellectual property rights, scientific and technological achievements, R&D organizational management, and the healthy growth of the enterprise.
Under the leadership of Chairman Zhu Baoguo, HealthGen has developed into an innovative R&D-oriented comprehensive pharmaceutical group covering multiple fields, including chemical preparations, traditional Chinese medicine preparations, chemical raw materials and intermediates, diagnostic reagents and equipment, and health products, with deep R&D accumulation. To date, HealthGen has developed and launched multiple high-quality inhalation preparation products. Its inhalation preparations have 7 varieties and 11 specifications approved for listing, with more than 30 projects under research. It has successfully achieved a diversified product matrix and a comprehensive pipeline of drugs under research, gradually breaking through technological barriers in the sub-sectors and establishing market competitive advantages. It has become a leading enterprise in the respiratory drug field that has broken the monopoly of multinational companies, continuously consolidating its leading position in the domestic high-end complex preparation field.
According to statistics from the Pharmaceutical Intelligence Listed Company Product R&D Details Database, HealthGen and its holding subsidiary Lizhu Group ranked seventh and ninth in the domestic pharmaceutical industry in 2021 in terms of R&D investment, respectively. The change rate ranked among the top four, which is at a relatively high level in the same industry.
At this year's "Leading Forces · China Pharmaceutical High-Quality Development Achievement Enterprises and Achievement Brands (2022)" release event held by the Pharmaceutical Economics News, Zhu Baoguo stated that 2023 is the opening year for implementing the spirit of the 20th National Congress of the Communist Party of China and a crucial year for implementing the "14th Five-Year Plan." China's pharmaceutical industry is steadily advancing, maintaining a good trend of innovative development on the path of high-quality development. We will seize opportunities, break through inertia and path dependence, accelerate the iterative development of the industry, and continuously push our own development to new heights.
Previously, many biopharmaceutical companies, including HealthGen, were investigated by institutions. Research institutions pay more attention to the transformation brought about by technological innovation for enterprises and the strength of enterprises in breaking through the transformation of innovative technologies. Shanghai Securities believes that with the upgrading and optimization of the industrial structure in the future, industry differentiation will become more obvious. It is recommended to focus on leading companies in high-quality sectors.
Source: Phoenix.com
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.